Malawi’s medicine shortage has become a test of the state

Patients are still leaving public hospitals without the medicines they were prescribed, a month after the government promised to end persistent shortages. The gap between official assurances and what is on the shelves has raised questions about the state of the health system.

Health authorities say progress is being made. Reports from hospitals in Blantyre, Lilongwe, Mzuzu and other districts suggest otherwise.

Essential medicines remain hard to get, so patients turn to private pharmacies or go without treatment. For households already struggling with rising living costs, neither option is sustainable.

The shortages point to wider pressures. Health budget documents and analyses cited by stakeholders show a system still heavily dependent on donor support and constrained by financing problems, foreign exchange shortages and weak supply chains.

The system is vulnerable when suppliers go unpaid or when imported medicines become harder to obtain.

The Central Medical Stores Trust (CMST) is reportedly owed billions of kwacha by suppliers, while government has built up arrears for drugs and medical supplies already delivered. Such pressures inevitably feed through to shelves across the public system.

Parliamentary Committee on Health chairperson Anthony Masamba has warned that failing to address stock-outs could prove costly as the country faces recurring threats from diseases such as malaria and cholera.

Shortages do more than inconvenience patients, he and others argue. They erode confidence in public healthcare and can worsen outcomes when treatment is delayed.

Patients describe a familiar pattern. A clinician writes a prescription, and the patient finds the medicine is out of stock. The prescription then becomes a bill at a private pharmacy, shifting a cost that should fall on the public system onto families.

For poorer households, treatment is often postponed or abandoned.

Government spokesperson Benedicto M’bwe says authorities are working with manufacturers and development partners to improve supplies and settle outstanding obligations. Such measures may ease the pressure in time.

Budget allocations alone do not guarantee that medicines reach patients. The 2026/27 allocation for medicines and medical supplies may look substantial on paper, but funding cannot by itself overcome procurement delays, debt and supply-chain weaknesses.

The shortage raises questions beyond health facilities about the state’s ability to turn policy commitments into services and to protect citizens from preventable hardship.

Until medicines are reliably available when prescribed, the crisis will remain a test of governance as much as a health problem.